Fifth Third Bancorp Immuno Gen, Inc. Transaction History

Fifth Third Bancorp

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	BUY	$3.15 - $5.76 $18 - $34	6 Added 2.04%	300 $1,000
Q1 2022 Apr 19, 2022	BUY	$4.26 - $7.48 $570 - $1,002	134 Added 83.75%	294 $1,000
Q3 2021 Oct 15, 2021	BUY	$5.02 - $6.59 $803 - $1,054	160 New	160 $1,000
Q2 2021 Aug 06, 2021	SELL	$5.79 - $8.6 $17,370 - $25,800	-3,000 Closed	0 $0
Q1 2021 May 07, 2021	SELL	$6.5 - $10.53 $19,500 - $31,589	-3,000 Reduced 50.0%	3,000 $24,000
Q4 2020 Feb 16, 2021	SELL	$3.7 - $7.66 $529 - $1,095	-143 Reduced 2.33%	6,000 $39,000
Q3 2020 Nov 09, 2020	BUY	$3.45 - $4.89 $493 - $699	143 Added 2.38%	6,143 $22,000
Q2 2020 Aug 05, 2020	SELL	$3.32 - $5.34 $41,768 - $67,182	-12,581 Reduced 67.71%	6,000 $28,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $2,126 - $3,247	-958 Reduced 4.9%	18,581 $45,000
Q2 2019 Aug 07, 2019	BUY	$1.8 - $3.3 $1,724 - $3,161	958 Added 5.16%	19,539 $42,000
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $114 - $281	-29 Reduced 0.16%	18,581 $89,000
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $249 - $326	29 Added 0.16%	18,610 $176,000
Q1 2018 May 15, 2018	BUY	$6.7 - $12.95 $84,292 - $162,923	12,581 Added 209.68%	18,581 $195,000
Q3 2017 Nov 14, 2017	SELL	$5.4 - $8.47 $3,780 - $5,929	-700 Reduced 10.45%	6,000 $46,000
Q2 2017 Aug 11, 2017	BUY	N/A	6,700	6,700 $48,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

Stay updated on Fifth Third Bancorp with notifications on news.